Elevidys Sales Beat Consensus, But Sequential Decline Triggers Stock Drop

Sarepta Therapeutics (SRPT) announced in its 2026 Q1 earnings that Elevidys (delandistrogene moxeparvovec), its gene therapy for Duchenne Muscular Dystrophy (DMD), generated $102 million in revenue. This figure exceeded Wall Street's expectations of $95 million; however, the continued sequential decline in sales caused the stock to plummet by over 10%, closing at $20.60. The market's sensitivity to the sequential decline, rather than the earnings beat, reflects lingering concerns about the long-term growth prospects of Elevidys.

2025 Safety Warning and Reduced Indication Limit Growth

In November 2025, Elevidys received a Boxed Warning from the U.S. Food and Drug Administration (FDA) and had its indication withdrawn for non-ambulatory patients due to a case of acute liver failure in a non-ambulatory patient receiving the therapy. This regulatory action significantly narrowed the target patient population to ambulatory patients aged 4 and older, severely impacting its position as a key growth driver. The high cost of treatment and stricter safety monitoring procedures are further hindering the influx of new patients, leading to stagnant sales.

Sarepta's Restructuring and RNA Platform Transition with Arrowhead License

Faced with growth challenges, Sarepta is diversifying its business structure by focusing on the development of small interfering RNA (siRNA) therapeutics, licensed from Arrowhead Pharmaceuticals (ARWR). In November 2024, the two companies entered into a major global licensing agreement worth up to $11.35 billion to co-develop a pipeline of therapies for rare genetic diseases. This strategic shift aims to diversify away from a single gene therapy and find new opportunities in the RNA therapy space, which offers relatively lower production costs.

Positive Early Results in Phase 1/2 Trials and Anticipated Additional Data in 2026

In March 2026, Sarepta announced initial data from Phase 1/2 trials of SRP-1001, a therapy for Facioscapulohumeral Muscular Dystrophy type 1 (FSHD1), and SRP-1003, a therapy for Myotonic Dystrophy type 1 (DM1), demonstrating promising results. Both candidates maintained high drug concentrations in muscle tissue and successfully suppressed target genes without causing serious adverse events, generating market interest. The company plans to release additional clinical data in the second half of 2026, and these results will determine Sarepta's medium- to long-term corporate value and its ability to establish a technological edge in the RNA field.

Major Restructuring and Doug Ingram's Planned Retirement as CEO

Over the past year, Sarepta has undertaken significant restructuring measures, including reducing its workforce by more than one-third and discontinuing some pipeline programs, in an effort to improve its financial health. Amidst this management upheaval, Doug Ingram, the company's Chief Executive Officer (CEO), announced his retirement at the end of 2026, marking another change in leadership. Market attention is now focused on the capabilities of Sarepta's next leadership team to overcome the challenges of gene therapy safety regulations and establish a successful new RNA platform.